The COHCCC Protocol Review and Monitoring System is implemented through the activities of its Cancer Protocol Review and Monitoring Committee (CPRMC). The CPRMC focuses on scientific merit, scientific priorities, and scientific progress of Cancer Center clinical research, working collaboratively with the Data and Safety Monitoring Committee (DSMC) in accordance with the COHCCC Data and Safety Monitoring Plan. The role of the CPRMC is to: 1) maintain and improve the quality of institutional clinical research;2) prioritize clinical research conducted by Cancer Center members;and 3) provide a pathway for innovative clinical cancer research to access Cancer Center shared resources and protocol specific research support. Committee review and voting is required for all new trials, amendments, and annual continuation reviews. The scientific review process for new trials includes an evaluation of study design, scientific rationale, feasibility and biostatistical methodology. Annual continuation reviews include an examination of actual vs. expected accrual and continued relevance of the research question. The CPRMC provides a centralized mechanism for evaluating the scientific merit of all cancer clinical trials and prioritizes studies for access to COHCCC clinical trial resources. Funding is requested for partial salary support for the Chair of the CPRMC, the Director of Scientific and Safety Review, two Protocol Analysts and a Clerical Specialist supporting the work of protocol review and monitoring. All other remaining costs are covered by institutional funds.

Public Health Relevance

It is of critical importance that the COHCCC have a mechanism for assuring adequate internal oversight of the scientific aspects of all cancer clinical trials. The PRMS addresses this. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-30
Application #
8450546
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2017-11-30
Budget Start
2013-04-25
Budget End
2013-11-30
Support Year
30
Fiscal Year
2013
Total Cost
$40,018
Indirect Cost
$16,197
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41
Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9
Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85
Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124
Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70
Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209
Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53
Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70

Showing the most recent 10 out of 912 publications